Novo Nordisk A/S (NONOF)
| Market Cap | 216.87B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | n/a |
| EPS (ttm) | 3.93 |
| PE Ratio | 12.40 |
| Forward PE | 13.62 |
| Dividend | 1.66 (3.39%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 100 |
| Average Volume | 86,224 |
| Open | 49.00 |
| Previous Close | 50.00 |
| Day's Range | 49.00 - 49.02 |
| 52-Week Range | 45.00 - 115.29 |
| Beta | 0.33 |
| RSI | 32.76 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Global week ahead: Is Novo Nordisk past 'peak uncertainty'?
CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.
Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks
Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.
Pfizer sues to block Novo Nordisk's bid for Metsera in high-stakes pharma clash
Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the Delaware Court of Chancery on October 31. The litigation challenges Novo's bombsh...
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Pfizer said Friday it filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations.
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.
Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulatory Progress
Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulatory Progress
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Megacap earnings to dominate next week as government shutdown continues. 11/3/25
The ongoing government shutdown is set to become the second-longest in U.S. history, creating a major hurdle for equities and commodities despite a trade truce with China and a recent Fed rate cut. 10...
Pfizer Faces Off With Novo Nordisk Over Metsera Bid
Pfizer Faces Off With Novo Nordisk Over Metsera Bid
Novo Nordisk (NVO) Implements Global Job Cuts Amidst Strategic Changes
Novo Nordisk (NVO) Implements Global Job Cuts Amidst Strategic Changes
Novo Nordisk CEO says job cuts affecting 9,000 staff almost complete
Novo Nordisk has notified employees impacted by the drugmaker's job cuts in the vast majority of its locations although the pace varies according to local laws, its CEO Mike Doustdar wrote in a post o...
Mizuho's Holtz talks what is behind Novo's bid for Metsera
Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat.
Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss
Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.
Pfizer (PFE) Contemplates Legal Action Against Metsera (MTSR) Following Novo Nordisk's (NVO) Offer
Pfizer (PFE) Contemplates Legal Action Against Metsera (MTSR) Following Novo Nordisk's (NVO) Offer
Pfizer considers suing Metsera, Novo over topping bid - report
Pfizer may sue Novo Nordisk and Metsera over a $9B takeover bid, alleging antitrust risks and regulatory evasion.
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde...
Metsera Shares Jump 24.98% As Novo Nordisk Launches $9 Bln Unsolicited Bid
(RTTNews) - Metsera, Inc. (MTSR) surged 24.98% to $65.25, gaining $13.04, after receiving an unsolicited proposal from Novo Nordisk valuing the company at up to $77.75 per share, approximately $9 bill...
Pfizer Fires Back as Novo Nordisk Hijacks Its $8.5 Billion Metsera Deal
Pfizer Fires Back as Novo Nordisk Hijacks Its $8.5 Billion Metsera Deal
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Metsera Becomes The Prize In Obesity's Biggest Bidding War
Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about MTSR stock here.
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera has become the obesity drug market's hottest ticket.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
On Thursday, Metsera Inc . (NASDAQ: MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE: NVO). Metsera said the proposal constitutes a “Superior Company Proposal” as defin...
Novo Nordisk bid for obesity-focused biotech firm could gazump Pfizer offer
Metsera viewed as a lucrative takeover target in part because of its promising research into weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for US obesity-focused biotech f...